Highlights of This Issue 321

SPECIAL FEATURES

CCR Translations

323  BAP1tism of a Tumor Suppressor
    Scott E. Woodman
    See article p. 408

Molecular Pathways

326  Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
    William C. Dougall

Perspective

336  New Challenges in Endpoints for Drug Development in Advanced Melanoma
    Antoni Ribas, Peter Hersey, Mark R. Middleton, Helen Gogas, Keith T. Flaherty, Vernon K. Sondak, and John M. Kirkwood

Review

342  Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
    Michaela R. Reagan and Irene M. Ghobrial

HUMAN CANCER BIOLOGY

350  Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
    Brooke E. Sylvester, Dezheng Huo, Andrey Khramtsov, Jing Zhang, Andrey Khramtsov, Dezheng Huo, Andrey Khramtsov, Jing Zhang, Rana V. Smalling, Sope Olugbile, Blase N. Polite, and Olufunmilayo I. Olopade

360  A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
    Rajasubramaniam Shanmugam, Padmaja Gade, Annique Wilson-Weekes, Hamid Sayar, Attaya Suvannsankha, Chirayu Goswami, Lang Li, Sushil Gupta, Angelo A. Cardoso, Tareq Al Baghdadi, Katie J. Sargent, Larry D. Cripe, Divanajaya V. Kalvakolanu, and H. Scott Boswell

CANCER THERAPY: PRECLINICAL

370  Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
    Rossitza Lazova, Robert L. Camp, Vincent Khlop, Summar F. Siddiqui, Ravi K. Amaravadi, and John M. Pawelek

380  Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
    Hsu-Fung Yuen, Ka-Kui Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osawa Sharaf Eldin, Ken O’Byrne, Pasi Janne, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, and Mohamed El-Tanani

392  Serum Interleukin-6, Insulin, and HOMA-IR in Male Individuals with Colorectal Adenoma
    Yu Sasaki, Hiroaki Takeda, Takeshi Sato, Tomohiko Ootii, Shoichi Nishise, Ko Nagino, Daisuke Iwano, Takao Yarita, Kazuya Yoshizawa, Hideki Saito, Yasuhisa Tanaka, and Sumio Kawata

400  Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
    Min-Han Tan, Jessica L. Mester, Joanne Ngeow, Lisa A. Rybicki, Mohammed S. Orloff, and Charis Eng

408  Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
    Solange Landreville, Olga A. Agapova, Katie A. Matatall, Zachary T. Knuss, Michael D. Onken, Ryan S. Lee, Anne M. Bowcock, and J. William Harbour

417  Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells
    Sascha Dietrich, Oliver H. Kramer, Esther Hahn, Claudia Schäfer, Thomas Giese, Michael Hess, Theresa Tretter, Michael Rieger, Jennifer Hullein, Thorsten Zenz, Anthony D. Ho, Peter Dreger, and Thomas Luft
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>442</td>
<td>Bexarotene via CBP/p300 Induces Suppression of NF-κB-Dependent Cell Growth and Invasion in Thyroid Cancer</td>
<td>Audrey Cras, Beatrice Politis, Nicole Balitrand, Diane Darsin-Bettinger, Pierre Yves Boelle, Bruno Cassinat, Marie-Elisabeth Toubert, and Christine Chomienne</td>
</tr>
<tr>
<td>454</td>
<td>Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth</td>
<td>Andreas Wicki, Christoph Bachlitz, Annette Orleth, Reto Ritschard, Enke Albrecht, Richard Herrmann, Gerhard Christofori, and Christoph Mamot</td>
</tr>
<tr>
<td>465</td>
<td>EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells</td>
<td>Michele Cioffi, Jorge Dorado, Patrick A. Baeuerle, and Christopher Heeschen</td>
</tr>
<tr>
<td>475</td>
<td>CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells</td>
<td>Daniela Trisciuoglio, Ylenia Ragazzoni, Andrea Pelosi, Marianna Desideri, Simone Carradori, Chiara Gubellini, Giovanna Maresca, Riccardo Nescaletti, Daniela Secchi, Adriana Bolasco, Bruna Bizzarri, Chiara Cavaliere, Igea D'Agnano, Patrizia Filetici, Lucia Ricci-Vitiani, Maria Giulia Rizzo, and Donatella Del Bufalo</td>
</tr>
<tr>
<td>499</td>
<td>VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC</td>
<td>Hailing Lu, Gregory N. Dietsch, Maura-Ann H. Matthews, Yi Yang, Smita Ghanekar, Margaret Inokuma, Maria Suni, Vernon C. Maino, Katherine E. Henderson, James Jeffry Howbert, Mary L. Disis, and Robert M. Hershberg</td>
</tr>
</tbody>
</table>

### IMAGING, DIAGNOSIS, PROGNOSIS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>524</td>
<td>Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer</td>
<td>Jih-Hsiang Lee, Elisa Giovannetti, Jin-Hyeok Hwang, Iacopo Petrini, Quyan Wang, Johannes Voortman, Yonghong Wang, Seth M. Steinberg, Niccola Funel, Paul S. Meltzer, Yisong Wang, and Giuseppe Giaccone</td>
</tr>
</tbody>
</table>

### CANCER THERAPY: CLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>555</td>
<td>Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma</td>
<td>John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazzulina, Karin Kemsley, and Reinhard Dummer</td>
</tr>
</tbody>
</table>
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty, Patricia M. LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia S. Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O'Dwyer, and Gary K. Schwartz

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303

Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non–Small Cell Lung Cancer Patients
Klaus W. Wagner, Yuanqing Ye, Jie Lin, Ara A. Vaporciyan, Jack A. Roth, and Xifeng Wu

ABOUT THE COVER

Although antiangiogenic therapies are effective and comparatively safe treatments against human cancer, renal toxicity is one of the major concerns. Anti-VEGFR2 immunoliposomes loaded with a chemotherapeutic drug showed marked antitumor activity in various tumor models. Importantly, no long-term renal side effects were evident with this therapy. This image shows a section of mouse kidneys 18 months after repeated injection of anti-VEGFR2 immunoliposomes loaded with doxorubicin. For details, see the article by Wicki and colleagues on page 454 of this issue.